The standard of care in locally advanced rectal cancer is neoadjuvant chemoradiation
(nCRT) followed by radical surgery. Response to nCRT varies among patients and …

Purpose To investigate the association between KRAS mutation and prognosis in rectal
cancer patients with neoadjuvant chemoradiotherapy. Methods Literature was searched in …

Background Mutation of the KRAS oncogene (mKRAS) in colorectal cancer has been
associated with aggressive tumor biology, resistance to epidermal growth factor inhibitors …

Locally advanced rectal cancers (LARC) are the subject of a rapidly evolving treatment
paradigm. The critical timepoints where management decisions are required during the care …

Somatic mutations bear great promise for use as biomarkers for personalized medicine, but
are often present only in low abundance in biological material and are therefore difficult to …

Background The impact of RAS/BRAF mutation on primary response rates after total
neoadjuvant therapy (TNT) in patients with advanced rectal cancer is unclear. The aim of …

Introduction Standard treatment for patients with locally advanced rectal cancer (LARC)
includes neoadjuvant chemoradiotherapy (nCRT) with fluoropyrimidines, followed by …

According to current guidelines, the current treatment for locally advanced rectal cancer is
neoadjuvant therapy, followed by a total mesorectal excision. However, radiosensitivity …

Purpose Our sincere hope is to establish the predictive factors of neoadjuvant chemotherapy
(NAC) response and provide patients with greater certainty regarding treatment outcomes …

Tumor response to preoperative chemoradiotherapy and postoperative survival differs
among patients with locally advanced rectal cancer. The objective was to find correlations of …